solid tumors – Discover Pharma

Welcome to Discover Pharma! Today is : October 26, 2026

solid tumors

Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
CuraCell highlights T-cell therapy advances for solid tumors on World Cancer Day
On World Cancer Day (today, February 4), CuraCell highlights its [...]

May 5, 2026
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook
Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

May 5, 2026
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Lonza’s Synaffix and Sidewinder enter multi-target license agreement for bispecific ADCs
Synaffix B.V., a Lonza company focused on clinical-stage antibody-drug conjugate [...]

May 5, 2026
Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas
University of Minnesota investigators awarded $665,000 in ScaleReady G-Rex Grant funding
Three research teams to advance manufacturing and development of cell [...]

May 5, 2026
Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas
Can cryoablation plus intratumora immunotherapy rewrite the rules of cancer treatment?
Q&A with Dr Jason Williams, founder of the Williams Cancer [...]

May 5, 2026
Advanced Therapies,Drug Discovery & Development
Domain Therapeutics shares updates on immuno-oncology programs at AACR 2025
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK